Ads
related to: what is bevacizumab (avastin) 2 10 mg flexeril look likePrescription-treatment-website.com has been visited by 10K+ users in the past month
everydayhealth.com has been visited by 10K+ users in the past month
Search results
Results From The WOW.Com Content Network
Bevacizumab, sold under the brand name Avastin among others, is a monoclonal antibody medication used to treat a number of types of cancers and a specific eye disease. [30] [28] For cancer, it is given by slow injection into a vein (intravenous) and used for colon cancer, lung cancer, ovarian cancer, glioblastoma, hepatocellular carcinoma, and renal-cell carcinoma. [31]
Anti-VEGF. Anti–vascular endothelial growth factor therapy, also known as anti-VEGF (/ vɛdʒˈɛf /) therapy or medication, is the use of medications that block vascular endothelial growth factor. This is done in the treatment of certain cancers and in age-related macular degeneration. They can involve monoclonal antibodies such as ...
Cyclobenzaprine is used, in conjunction with physical therapy, to treat muscle spasms that occur because of acute musculoskeletal conditions. [11] After sustaining an injury, muscle spasms occur to stabilize the affected body part, which may increase pain to prevent further damage. Cyclobenzaprine is used to treat such muscle spasms associated ...
Intravitreal injection is the method of administration of drugs into the eye by injection with a fine needle. The medication will be directly applied into the vitreous humor. [1] It is used to treat various eye diseases, such as age-related macular degeneration (AMD), diabetic retinopathy, and infections inside the eye such as endophthalmitis. [1]
Sunitinib is approved for the treatment of metastatic renal cell carcinoma. Other therapeutic options in this setting are pazopanib (Votrient), sorafenib (Nexavar), temsirolimus (Torisel), interleukin-2 (Proleukin), everolimus (Afinitor), bevacizumab (Avastin), and aldesleukin. Renal cell carcinoma is generally resistant to chemotherapy or ...
Ranibizumab, sold under the brand name Lucentis among others, is a monoclonal antibody fragment created from the same parent mouse antibody as bevacizumab.It is an anti-angiogenic [16] that is approved to treat the "wet" type of age-related macular degeneration (AMD, also ARMD), diabetic retinopathy, and macular edema due to branch retinal vein occlusion or central retinal vein occlusion.